NFE2L2 and Beta-thalassemia: HMOX1 has also been reported as upregulated in two hereditary blood diseases, sickle cell disease and beta-Thalassemia, where NRF2 activation can potentially alleviate disease severity by reducing oxidative damage, inhibiting haemoglobin S polymerization, and promoting foetal haemoglobin expression [89].